Fimasartan Achieving SBP Target (FAST) Study

Condition(s) targeted: Essential,Hypertension

Intervention: Placebo (Drug); Fimasartan (Drug); Valsartan (Drug); Olmesartan medoxomil (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Boryung Pharmaceutical Co., Ltd

Official(s) and/or principal investigator(s):
KI-BAE SEUNG, Ph.D, Study Chair, Affiliation: Cardiovascular center, Seoul St.Mary's Hospital, The Catholic University of Korea

Overall contact:
Hyung-Jin Jung, Phone: +82-2-708-8233, Email: hjjung@boryung.co.kr

The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to Valsartan and Olmesartan(reference group) in patients with mild to moderate essential hypertension. Patients have 2 weeks of placebo run-in and wash out period, 2 weeks of taking required dose and 4 weeks of taking double dose.

Official title: A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change of sitting SBP from baseline after taking investigational products for 6 weeks.

Detailed description: A randomized, double-blind, active control, 3-parallel group comparison clinical study to evaluate the anti-hypertensive efficacy and safety of Fimasartan in patients with mild to moderate hypertension. Approximately 360 patients will be enrolled in 8 centers in South Korea. This study has planned 6 visits during 8 weeks.(2 weeks of placebo run-in and wash out, 2 weeks of treatment and 4 weeks of forced titration) All of the subjects who agreed to participate in this study and gave written informed consent voluntarily are assessed the inclusion and exclusion criteria and receive the investigational product(placebo) at screening visit. During more than 14 days of placebo run-in and wash out period, subjects have to stop the previous anti-hypertensive drug. After placebo run-in and wash out period, Subjects are assessed the final eligibility and started measuring ambulatory blood pressure for 24 hours. Subjects who determined to be appropriate for this study are allocated to experimental group(Fimasartan 60mg) or control group(Valsartan 80mg) or Reference group(Olmesartan 10mg) randomly at ratio 3: 3:1. Subjects take their investigational products daily for 2 weeks and double dose for 4 weeks. The placebo period will be single-blinded and the treatment allocation in this study will be double-blinded.

Minimum age: 19 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Subjects who voluntarily signed informed consent for participating in this clinical trial 2. Male and female between 19 and 70 years old 3. Subjects whose mean sitting SBP(siSBP) of 3 measurements is above 140mmHg at visit 2 with mild to moderate essential hypertension (Subjects who have not taken anti-hypertensive drugs within 3 months should have mean siSBP above 140mmHg at visit 1) 4. Subject who can understand the trial procedures and be willing to cooperate the trial Exclusion Criteria: 1. Severe hypertension patients with mean siSBP ≥ 180mmHg or siDBP ≥110mmHg at the assessment of Screening visit(Visit1) and Baseline visit (Visit2). 2. Patients whose difference between maximum and minimum among 3 times of blood pressure measurement is over 20mmHg(siSBP) or 10mmHg(siDBP) at visit1 and visit2. 3. Patients whose medication compliance is under 70% at visit 2. 4. Secondary hypertension patients, but not limited to the following diseases (example: renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc). 5. Patients who have postural hypotension with manifestation. 6. Subjects with severe insulin-dependent Diabetes Mellitus(DM) or uncontrolled DM(HbA1c > 9% at screening visit, modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit, or currently use of active insulin treatment). 7. History of malignant tumor including leukemia and lymphoma in the past 5 years. 8. Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy, past or current medical history with wasting disease, autoimmune diseases (e. g. rheumatoid arthritis, systemic lupus erythematosus) or connective tissue disease. 9. Medical history with hypersensitivity to angiotensin II antagonist. 10. Clinically significant renal and liver disorders such as dialysis, cirrhosis, biliary obstruction, cholestasis and liver failure. Patients who have below abnormality in the laboratory results at screening visit.

- Creatinine clearance(Cockroft-Gault)<30mL/min

- ALT, AST ≥ 2 times upper normal limit

- Clinically significant hypokalemia(K<3. 5mmol/L) or hyperkalemia(K>5. 5mmol/L)

11. Subjects have history of any of the followings within the past 6 months or determined clinically significant by investigators.

- Severe heart disease (Heart failure New York Heart Association(NYHA) class 3 and

4), ischemic heart disease (angina pectoris, myocardial infarction), peripheral vascular disease, percutaneous transluminal coronary angioplasty or coronary artery bypass graft.

- Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery

disease, aortic stenosis, hemodynamically significant aortic valve stenosis, or mitral valve stenosis.

- Clinically significant ventricular tachycardia, atrial fibrillation, atrial

flutter or any other clinical significant arrhythmia.

- Severe cerebrovascular disorder(e. g.stroke, cerebral infarction or cerebral

hemorrhage) 12. Subjects with known moderate or malignant retinosis in the past 6 months (e. g. retinal hemorrhage, visual disturbance or retinal microaneurysm) 13. Subjects with history of abusing drugs or alcohol within the past 2 years. 14. Pregnant women or lactating female. 15. Subjects with following surgical and internal disease that may affect absorption, distribution, metabolism or excretion of drugs and have conditions which include the following (but are not limited to): history of major gastrointestinal surgeries including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass graft and stabling; current active gastritis, gastrointestinal and rectal bleeding, presence of active inflammatory bowel syndrome within the past 12 months. 16. Subjects with shock, depletion of body fluid or sodium ion not able to correct. 17. Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. 18. Medical history with clinically significant hypersensitivity to any components or other drugs on the investigational product or additives(yellow4 and yellow 5). 19. Subjects planning pregnancy or childbearing potential who are not using effective contraceptive methods. 20. Subjects who are participating in another trial or took other investigational product within 12 weeks prior to screening visit. 21. Subjects with other reasons not specified above and ineligible to participate in this clinical trial at discretion of study investigators.

Hyung-Jin Jung, Phone: +82-2-708-8233, Email: hjjung@boryung.co.kr

The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Banpo-dong, Seocho-gu 137-701, Korea, Republic of; Recruiting
KI-BAE SEUNG, Ph.D., Phone: +82-2-2258-1071, Email: kbseung@catholic.ac.kr

The Catholic University of Korea, Incheon St.Mary's Hospital, Incheon, Bupyeong-gu 403-720, Korea, Republic of; Recruiting
Doo-Soo Jeon, Ph.D, Phone: +82-32-280-5163, Email: coronary@catholic.ac.kr

The Catholic University of Korea, St. Paul's Hospital, Seoul, Dongdaemun-gu 130-709, Korea, Republic of; Recruiting
Byung-Hee Hwang, M.D., Phone: +81-2-958-4538, Email: hbhmac@naver.com

The Catholic University of Korea, St.Vincent's Hospital., Suwon-si, Gyeonggi-do 442-723, Korea, Republic of; Recruiting
Ki-Dong Yoo, Ph.D, Phone: +82-31-749-7123, Email: yookd@catholic.ac.kr

The Catholic University of Korea,Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do 480-717, Korea, Republic of; Recruiting
Jong-Min Lee, Ph.D, Phone: +82-10-3883-6683, Email: leejongm@catholic.ac.kr

The Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon, Jung-gu/Daeheung-ro 301-723, Korea, Republic of; Recruiting
Sung-Ho Her, PhD, Phone: +81-42-220-9686, Email: hhhsungho@hanmail.net

The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon, Kyunggi-Do 420-717, Korea, Republic of; Recruiting
Sang-Hyun Ihm, Ph.D, Phone: +81-32-340-7027, Email: heartihmsh@yahoo.co.kr

The Catholic University of Korea,Yeouido St.Mary's Hospital, Seoul, Yeongdeungpo-gu 150-713, Korea, Republic of; Recruiting
Woo-Baek Chung, MD, Phone: +82-2-3779-1060, Email: peace816@catholic.ac.kr

Starting date: June 2015
Last updated: July 8, 2015